Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: A propensity score weighted multicenter cohort study
European Journal of Clinical Microbiology & Infectious Diseases Jan 28, 2018
Ko JH, et al. - The efficacy of empirical non-carbapenem antibiotics for extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia (ESBL-B) was evaluated in a multicenter retrospective cohort study. For ESBL-B, appropriate non-carbapenems proved not inferior to carbapenems as initial empirical therapy.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
